TrovaGene Inc Stock Nasdaq
Equities
US8972383090
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 242K | Sales 2025 * | 66.67K | Capitalization | 178M |
---|---|---|---|---|---|
Net income 2024 * | -46M | Net income 2025 * | -57M | EV / Sales 2024 * | 735 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2,674 x |
P/E ratio 2024 * |
-4.09
x | P/E ratio 2025 * |
-3.79
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.32% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |